BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

Reuters
03-03
BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

March 3 (Reuters) - Takeda Pharmaceutical 4502.T:

  • PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA

  • PROTAGONIST THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT WITH HIGHER CLINICAL RESPONDERS ON RUSFERTIDE

  • PROTAGONIST THERAPEUTICS INC - ALL FOUR KEY SECONDARY ENDPOINTS MET IN VERIFY STUDY

  • PROTAGONIST THERAPEUTICS INC - RUSFERTIDE GENERALLY WELL TOLERATED WITH NO NEW SAFETY FINDINGS

  • PROTAGONIST THERAPEUTICS INC - IMPACT ON TAKEDA'S FY2024 FINANCIAL RESULTS IS IMMATERIAL

Source text: ID:nBwbPzjCsa

Further company coverage: 4502.T

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10